The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in oncology. One of the key reasons lies in the disease's unique fibrotic ...

Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...

A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the ...

Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in oncology. One of the key reasons lies in the disease's unique fibrotic ...

The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).

A study in the current journal Oncotarget provides the first evidence linking a disturbance of the most common protein in the body with a poor outcome in pancreatic cancer. The study reinforces ...

Discoidin domain receptor tyrosine kinase 1 (DDR1) contributes to tumor progression by promoting the alignment and densification of collagen fibers within the extracellular matrix (ECM), thereby ...

Collagen plays dual roles in pancreatic cancer: as a physical fiber that obstructs macromolecular drug delivery, and as a bioactive signaling molecule that activates discoidin domain receptor 1 (DDR1) ...